Outlook Therapeutics, INC Form 4 insider transactions

Faisal Ghiath Sukhtian, a director of Outlook Therapeutics, received stock options under the company's 2024 Equity Incentive Plan.

Director Kurt Hilzinger received multiple stock option grants from Outlook Therapeutics, vesting over the next year, according to a recent SEC filing.

Randy H. Thurman, a director at Outlook Therapeutics, received two stock option grants on October 1, 2024, which will fully vest on October 1, 2025, subject to continuous service.

Lawrence Kenyon, CFO of Outlook Therapeutics, recently purchased 5,000 shares of the company's common stock at a price of $5.6892 per share.

Syntone Ventures LLC acquired 714,286 shares of common stock and warrants to purchase 1,071,429 shares of common stock in a private placement by Outlook Therapeutics, Inc. on April 15, 2024.

Director Yezan Munther Haddadin purchased 1,881.7112 shares of Outlook Therapeutics at a weighted average price of $11.82 per share on March 28, 2024.

Outlook Therapeutics CEO, C. Russell Trenary III, acquired 455,000 stock options on March 20, 2024, according to a Form 4 filing with the SEC.

Jeff Evanson, Chief Commercial Officer of Outlook Therapeutics, acquired 25,000 stock options on March 20, 2024, according to a Form 4 filing with the SEC.

Lawrence Kenyon, CFO of Outlook Therapeutics, acquired stock options for 12,500 shares on March 20, 2024.

Ghiath M. Sukhtian, a director and 10% owner of Outlook Therapeutics, acquired shares and warrants through a private placement, increasing his indirect holdings in the company.

Jeff Evanson, Chief Commercial Officer of Outlook Therapeutics, recently purchased 62,484 shares of the company's common stock at an average price of $0.42 per share.

Julia Haller, a director at Outlook Therapeutics, acquired 94,441 stock options on March 7, 2024, under the company's 2015 Equity Incentive Plan.

Director Andong Huang received stock options for 94,441 shares of Outlook Therapeutics, Inc. at an exercise price of $0.41 on March 7, 2024.

Director Gerd Auffarth received stock options for 94,441 shares of Outlook Therapeutics, Inc. at an exercise price of $0.41 on March 7, 2024.

Director Julian S. Gangolli acquired 94,441 stock options in Outlook Therapeutics, Inc. on March 7, 2024.

Director Yezan Munther Haddadin acquired 94,441 stock options in Outlook Therapeutics, Inc. on March 7, 2024.

Faisal Ghiath Sukhtian, a director of Outlook Therapeutics, acquired stock options for 94,441 shares on March 7, 2024.

Director Kurt Hilzinger acquired 94,441 stock options in Outlook Therapeutics, Inc. on March 7, 2024.

Director Randy H. Thurman acquired 94,441 stock options in Outlook Therapeutics, Inc. on March 7, 2024.